Evidence map›Paper›PMID 29164777›Full record

ArticleJournal of biomedical materials research. Part A2018

Formulation and characterization of poly(propylacrylic acid)/poly(lactic-co-glycolic acid) blend microparticles for pH-dependent membrane disruption and cytosolic delivery.

Lawrence P Fernando, Jamal S Lewis, Brian C Evans, Craig L Duvall, Benjamin G Keselowsky

Abstract read
In one paragraph

Article in Journal of biomedical materials research. Part A, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Lawrence P FernandoJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida.
Jamal S LewisDepartment of Biomedical Engineering, University of California, Davis, Davis, California.
Brian C EvansDivision of Vascular Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Craig L DuvallDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee.
Benjamin G KeselowskyJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida.
University of Florida · USUniversity of California, Davis · USVanderbilt University · USVanderbilt University Medical Center · US

Funding

Tolerogenic dual microparticle system for treatment of multiple sclerosisR01AI133623 · NIAID · UNIVERSITY OF FLORIDA · PI AVRAM, DORINA, KESELOWSKY, BENJAMIN GEORGE · 2017 to 2021
$2.6M
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft PatencyR01HL122347 · NHLBI · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2016 to 2020
$2.2M
Tissue-Targeted Enzyme for Localized Tryptophan Catabolism to Direct Subcutaneous and Oral Mucosal Inflammatory ResponsesR01DE027301 · NIDCR · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2017 to 2020
$2.0M
Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery of InR01DK091658 · NIDDK · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2012 to 2016
$1.6M
Biomaterial Delivery System for Type 1 Diabetes VaccineR01DK098589 · NIDDK · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2014 to 2017
$1.5M
Smart Polymer Based MK2 Inhibitor to Suppress Vascular Graft Intimal HyperplasiaR21HL110056 · NHLBI · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2011 to 2012
$403k
High-Throughput Evaluation of Dendritic Cell-Targeting Vaccine Particles for theR21AI094360 · NIAID · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2012 to 2013
$388k
NHLBI NIH HHS R01 HL122347NHLBI NIH HHS R21 HL110056NIAID NIH HHS R01 AI133623NIAID NIH HHS R21 AI094360NIDCR NIH HHS R01 DE027301NIDDK NIH HHS R01 DK091658NIDDK NIH HHS R01 DK098589
6 · The paper itself

Abstract

Poly(lactic-co-glycolic acid) (PLGA) is widely used as a vehicle for delivery of pharmaceutically relevant payloads. PLGA is readily fabricated as a nano- or microparticle (MP) matrix to load both hydrophobic and hydrophilic small molecular drugs as well as biomacromolecules such as nucleic acids and proteins. However, targeting such payloads to the cell cytosol is often limited by MP entrapment and degradation within acidic endolysosomes. Poly(propylacrylic acid) (PPAA) is a polyelectrolyte polymer with the membrane disruptive capability triggered at low pH. PPAA has been previously formulated in various carrier configurations to enable cytosolic payload delivery, but requires sophisticated carrier design. Taking advantage of PPAA functionality, we have incorporated PPAA into PLGA MPs as a simple polymer mixture to enhance cytosolic delivery of PLGA-encapsulated payloads. Rhodamine loaded PLGA and PPAA/PLGA blend MPs were prepared by a modified nanoprecipitation method. Incorporation of PPAA into PLGA MPs had little to no effect on the size, shape, or loading efficiency, and evidenced no toxicity in Chinese hamster ovary epithelial cells. Notably, incorporation of PPAA into PLGA MPs enabled pH-dependent membrane disruption in a hemolysis assay, and a three-fold increased endosomal escape and cytosolic delivery in dendritic cells after 2 h of MP uptake. These results demonstrate that a simple PLGA/PPAA polymer blend is readily fabricated into composite MPs, enabling cytosolic delivery of an encapsulated payload. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 1022-1033, 2018.

Indexed as

MicrospheresAcrylic ResinsAnimalsCell DeathCell MembraneCHO CellsCricetinaeCricetulusCytosolDendritic CellsEndocytosisEndosomesHumansHydrogen-Ion ConcentrationMice, Inbred C57BLParticle SizeAcrylic ResinsPolylactic Acid-Polyglycolic Acid Copolymercontrolled releasedrug deliveryendolysosomal escapepH-responsive polymerPLGApolymer-blend microparticles

Identifiers

PMID29164777
PMCPMC5851279
OpenAlexW2769010245

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.